The content on this site is intended for healthcare professionals only
Dr Ghorashian speaks with ecancertv at Childhood Cancer 2016 about results from a European trial of CD19 CAR T cells to treat relapsed ALL.
She describes the creation, transduction and activation of the T cell line, and that vaccination of patients did result in short term benefit.
Dr Ghorashian considers that broader impact of engineered T cells, and looks forward to a second generation of CAR cells for her further research.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Revolutionising myeloma treatment through immune profiling
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Advancements in paediatric Acute lymphoblastic leukemia management
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Multiple myeloma In Rwanda: The need for further research
EHA 2024: Multiple myeloma roundup
Multiple myeloma in a resource constrained setting
